在长三角腹地的常熟市海虞镇，一座曾以传统制造为主的苏南小镇，正悄然崛起为硬科技企业集聚的新高 地。 这里没有一线城市密集的资本与人才光环，却凭借海虞镇经济发展科技服务团队和一套"创业者服务创业 者"的务实理念，吸引了一批专注新材料、新能源、医疗器械等前沿领域的高科技项目落地生根。 他们中有的致力于打破国外垄断的氢燃料电池核心材料国产化，有的聚焦口腔医学修复材料出海东南亚，还 有的用轻量化泡沫技术撬动风电与低空经济新蓝海。这一切的背后，离不开海虞科创政策和启迪之星(常熟)这 一"县域创新加速器"的深度赋能。从"一粒胶"到"一片林"，海虞镇正以"小切口"撬动"大产业"，书写着中国县 域经济从"跟跑"迈向"领跑"的新范式。 硬核企业扎堆落户：从"卡脖子"技术到国际赛道 走进海虞镇新材料协同创新谷，层高5米多、单层千平方米的现代化厂房里，多家硬科技企业正紧锣密鼓调试 设备、推进量产。其中，上海派行新能源科技有限公司的研发团队已在此扎根三年。作为国内少数掌握氢燃 料电池气体扩散层核心技术的企业，其自主研发的仿生多孔碳纤维材料，实现了纳米级孔结构的均匀可控， 良品率突破99%，性能甚至略优于韩国进口产品，而成本却控制在每 ...

爱迪特在接受投资者调研时表示，毛利率是产品市场竞争力关键要素，公司提高毛利率的主要策略是研 发创新，通过新产品开发和上市获得差异化溢价；通过优化工艺以及自动化生产提高制造品质和效率从 而降低生产成本。另外，公司正在供应链战略方面积极布局，与供应商联动共同推动提质提效目标实 现。 编辑 杨娟娟 校对 刘军 新京报贝壳财经讯（记者丁爽）12月30日，爱迪特发布的投资者关系活动记录表显示，公司在接受投资 者调研时回应耗材集采的可能性及对公司的潜在影响。爱迪特称，截至目前，公司耗材产品尚未列入集 采范围，公司也未收到相关组织方正式通知。 公司进一步表示，若未来被纳入，公司具备原料自产、产能充足、技术领先等竞争壁垒，对整体业绩影 响可控。 爱迪特主营业务覆盖口腔修复材料及口腔数字化设备。2025年前三季度，公司营收、归母净利润分别为 7.47亿元、1.42亿元。 受所处业务领域行业特性差异影响，爱迪特两业务板块的盈利表现呈现分化态势。公司在2025年半年报 中表示，报告期内，口腔修复材料产品毛利率为58.2%，较上年同期的60.36%有所下降，主要系公司为 提升市场占有率调整折扣框架所致；数字化设备业务方面，公司通过持 ...

爱迪特（301580.SZ）12月26日在投资者互动平台表示，除公司控股子公司韩国沃兰在韩国建有工厂生 产口腔种植体外，公司未在国外建厂生产口腔修复材料。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：贵司在国外有口腔修复材料生产工厂么？ ...

每经AI快讯，有投资者在投资者互动平台提问：请介绍一下义齿智能制造全无人自动化产线项目，是 直接生产假牙义齿吗，订单国内国外都可否？ 爱迪特（301580.SZ）12月16日在投资者互动平台表示，尊敬的投资者，您好。爱迪特销售的产品主要 包括口腔修复材料、口腔数字化设备等，义齿为义齿技工所生产和销售的产品，谢谢！ （文章来源：每日经济新闻） ...

登录新浪财经APP 搜索【信披】查看更多考评等级 一纸以股权抵偿交易差价的协议，让海利生物（603718.SH）再次成为资本市场关注的焦点。公司近日 宣布，将以约3.993亿元的对价收购子公司瑞盛生物剩余41%股权，而该笔款项实际为之前收购差价形 成的"债转股"。从高调进军口腔修复材料领域，到标的业绩迅速变脸、估值大幅缩水，这场始于2024年 10月的收购，在短短一年内已显露出多重风险与争议。 一、交易定价与履约能力存疑，关联交易认定"迟到" 2024年10月，海利生物以9.35亿元收购瑞盛生物55%股权，当时标的估值高达17亿元。然而随着行业价 格战加剧及税收政策变化，瑞盛生物业绩迅速下滑，2025年第二季度产品价格降幅达40%。海利生物随 后与出售方美伦公司签订补充协议，将估值调降至9.74亿元，收购价相应调减至5.357亿元，美伦公司需 退还3.993亿元差价。 然而，美伦公司已表示因"资金周转困难"无法支付该笔现金，最终以股权抵债。这引发了市场对其未来 能否履行业绩补偿承诺的担忧——根据调整后的承诺，瑞盛生物2024-2026年累计净利润需不低于2.33 亿元，剩余两年仍需完成约9500万元。 结语 ...

Core Viewpoint - The company Aidi Te achieved a closing price of 43.5 yuan on November 24, with a PE ratio of 25.62 and a total market value of 4.636 billion yuan, indicating a strong performance compared to the industry average [1] Company Summary - Aidi Te specializes in the research, production, and sales of dental restoration materials and digital dental equipment, holding 163 valid patents with complete independent intellectual property rights [1] - The company has been recognized as a national high-tech enterprise since November 2013 and was designated as a national-level "specialized, refined, and innovative" small giant enterprise in July 2024 [1] - For the third quarter of 2025, Aidi Te reported a revenue of 747 million yuan, a year-on-year increase of 16.44%, and a net profit of 142 million yuan, reflecting a year-on-year increase of 27.40% with a gross profit margin of 52.13% [1] Industry Summary - The average PE ratio for the medical device industry is 52.19, with a median of 40.14, positioning Aidi Te at the 52nd rank within the industry [2] - The company’s PE ratio of 25.62 is significantly lower than the industry average, suggesting potential undervaluation [2] - The total market value of the medical device industry is approximately 109.78 billion yuan, with Aidi Te's market value contributing to the overall sector [2]

Core Viewpoint - The company's performance in the first half of 2025 meets expectations, with strong growth in overseas business. Looking ahead to Q3 and the second half of 2025, the company is actively expanding its overseas market, expecting foreign income to maintain rapid growth. In the domestic market, the company anticipates that the revenue growth rate will exceed that of 2024 through the synergistic development of chairside repair systems, implant business, and repair materials [1][4][6]. Financial Performance - In the first half of 2025, the company achieved revenue of 486 million yuan, a year-on-year increase of 17.22%, and a net profit attributable to shareholders of 92 million yuan, up 19.86%. The net profit excluding non-recurring items was 84 million yuan, reflecting a growth of 9.35% [2][4]. - For Q2 2025, the company reported revenue of 280 million yuan, a year-on-year increase of 16.61% and a quarter-on-quarter increase of 36.52%. The net profit attributable to shareholders was 61 million yuan, up 13.61% year-on-year and 94.34% quarter-on-quarter [4]. Business Segments - The core business of dental repair materials showed steady growth, with revenue of 358 million yuan in the first half of 2025, a year-on-year increase of 19.19%, accounting for 73.74% of total revenue. The revenue from digital dental equipment was 96 million yuan, up 3.64% year-on-year, representing 19.80% of total revenue [5]. - The overall gross margin for the first half of 2025 was approximately 51.94%, slightly down year-on-year. The gross margin for dental repair materials was 58.20%, down 2.17 percentage points, while the gross margin for digital dental equipment was 30.50%, up 1.24 percentage points [5]. Research and Development - The company increased its R&D investment, with R&D expenses reaching 28 million yuan, a year-on-year increase of 36.12%, representing 5.82% of revenue. This increase is attributed to the hiring of additional R&D personnel and higher costs for new product registrations [6]. Strategic Outlook - The company aims to consolidate its leading position in the dental repair materials sector and build long-term competitiveness through a "materials + equipment + implants" collaborative development strategy [7][8]. - The company is enhancing its global layout, with overseas markets becoming a significant driver of revenue growth, as evidenced by a 34% year-on-year increase in foreign income in the first half of 2025 [9]. Revenue Forecast - The company forecasts revenues of 1.034 billion yuan, 1.205 billion yuan, and 1.407 billion yuan for 2025, 2026, and 2027, respectively, representing year-on-year increases of 16.4%, 16.56%, and 16.73%. The net profit attributable to shareholders is projected to be 180 million yuan, 217 million yuan, and 262 million yuan for the same years, with growth rates of 19.33%, 20.73%, and 20.78% [10].

Core Viewpoint - Aidi Te (Qinhuangdao) Technology Co., Ltd. has seen a stock price increase of 3.34% with a market capitalization of 4.847 billion yuan, benefiting from its focus on dental medical materials and 3D printing technology [1][2]. Company Overview - Aidi Te specializes in the research, production, and sales of dental restoration materials and digital dental equipment, with main products including dental restoration materials, digital dental devices, orthodontic products, and preventive dental products [2][4]. - The company has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, indicating its strong innovation capabilities and high market share in niche markets [3]. - As of June 30, 2025, Aidi Te's revenue composition includes 73.74% from dental restoration materials, 19.80% from digital dental equipment, and 6.46% from other products and services [8]. Financial Performance - For the first half of 2025, Aidi Te achieved a revenue of 486 million yuan, representing a year-on-year growth of 17.22%, and a net profit attributable to shareholders of 92.04 million yuan, up 19.86% year-on-year [8]. - The company's overseas revenue accounted for 61.85% of total revenue, benefiting from the depreciation of the Chinese yuan [4]. Market Activity - On October 9, the stock recorded a trading volume of 77.8274 million yuan with a turnover rate of 2.41%, indicating active market participation [1]. - The main capital inflow for the day was 3.862 million yuan, with a slight increase in main capital positions over the past two days [5][6]. Technical Analysis - The average trading cost of the stock is 47.91 yuan, with the current price approaching a support level of 44.05 yuan, suggesting potential volatility in the near term [7].

Core Viewpoint - The company, Haili Biological, is facing challenges after a high-premium acquisition of 55% of Shaanxi Ruisheng Biological Technology Co., Ltd. for 935 million yuan, which has not met expectations due to intensified market competition and declining product prices [1][2][3]. Group 1: Acquisition Details - Haili Biological announced a price adjustment for the acquisition of Ruisheng Biological, reducing the purchase price to approximately 536 million yuan, with the seller returning about 399 million yuan [1][3]. - The initial valuation of Ruisheng Biological was 1.94 billion yuan, with a significant premium of 321.11% at the time of acquisition [2]. - The acquisition was intended to facilitate Haili's transition into the oral tissue repair and regeneration materials sector [2][3]. Group 2: Market Conditions - Since the acquisition, the market has seen the approval of around 20 similar products, leading to aggressive price competition that has forced Ruisheng Biological to lower its prices significantly [3]. - In the second quarter of 2025, Ruisheng's product prices dropped by 40%, impacting profitability despite a slight increase in market share [3][6]. - Changes in tax policies have also negatively affected Ruisheng's financial performance, shifting from a simplified tax rate of 3% to a general tax rate of 13% [3]. Group 3: Financial Performance - Haili Biological's overall profitability has been weak, with net profits fluctuating below 100 million yuan since its IPO in 2015 [1][4][5]. - In 2024, Haili reported a net profit of 171 million yuan, a year-on-year increase of 172.28%, but the adjusted net profit was only 11 million yuan, reflecting a 10.49% decline [5]. - For the first half of 2025, Ruisheng Biological's revenue and net profit were significantly lower than half of its 2024 figures, indicating ongoing financial pressure [6].

Core Viewpoint - The Ministry of Industry and Information Technology and the National Medical Products Administration have announced the list of selected units for the second batch of the innovative task for biomedical materials, highlighting Jiangsu's leading position in this field with 20 projects selected, the highest in the country [1] Group 1: Project Overview - The biomedical materials innovation task aims to address critical technological challenges in the field and select the most capable innovators for focused breakthroughs in high-end medical materials [1] - Jiangsu's selected projects cover 14 categories of biomedical materials across three directions: inorganic non-metallic materials, polymer materials, and metal materials [1] Group 2: Application and Market Potential - These biomedical materials are widely used in high-value medical devices such as artificial joints, vascular stents, artificial bone repair, oral repair, and wound repair, indicating significant clinical application value and market promotion potential [1] - The increase in the number of applications and selections from Jiangsu compared to the previous round demonstrates substantial growth and potential for new growth points in the integration of new material clusters and biomedicine clusters [1] Group 3: Support and Development - Selected enterprises will receive policy support in financing, review, and registration after completing their tasks, which will accelerate the market launch process of biomedical materials and medical device products in Jiangsu [1]